Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
BioSpace6d
AbbVie Shares Plummet 12% as Cerevel Schizophrenia Asset Fails Phase II Trials
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
Hosted on MSN5d
AbbVie’s stock plummets over 12% after schizophrenia drug flops in Phase II trials
The acquisition gave BMS control of Karuna’s lead asset, KarXT (xanomeline-trospium), an antipsychotic with a novel mechanism ...
GlobalData on MSN18d
Zai Lab presents positive outcomes from KarXT Phase III trial for schizophrenia
Zai Lab has reported positive outcomes from its Phase III clinical trial of KarXT (xanomeline and trospium chloride) in China ...
FierceBiotech6d
AbbVie's $9B schizophrenia prospect flunks phase 2 trials, handing advantage to BMS
Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
ndtvprofit5d
Neuland Labs Share Price Hits Record High As KarXT Gains Focus After AbbVie Drug Setback
Neuland Labs share price surged after AbbVie’s emraclidine trial setback shifted focus to KarXT. As the exclusive Xanomaline ...
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
Zai Lab presents data from Phase 3 of KarXT for schizophrenia in China
Zai Lab (ZLAB) announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety and efficacy of ...
Business Wire19d
Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety and efficacy of KarXT ...